Outlook Therapeutics is trading 6.14% down now at $0.64 as investors continue to absorb the impact of its discounted $55 million stock-and-warrant offering.
- The financing priced securities at $0.99 per share and warrant, creating substantial dilution and potential warrant overhang for existing shareholders.
- The Nasdaq Composite is down 1.37%, adding pressure to risk-sensitive biotech shares.
- The stock has fallen five consecutive sessions, from $1.15 on August 10, 2026, to $0.64 currently.